Payment overview · 2025
General Payments
$498.70
25 reported records · 8 companies
Healthcare provider profile · identity verified
William Andrew Eason, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SELMER, TN · NPI 1821025867
Verified facts
What the public records show
CMS Open Payments records show William Andrew Eason, M.D. received $498.70 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $248.99 | 49.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.55 | 15.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.85 | 10.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.95 | 6.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.73 | 6.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.95 | 4.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.28 | 3.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.40 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $498.70 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $149.42 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $99.57 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.85 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.85 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.70 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
83 | 64 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 657 | 148 |
| Gabapentin | Gabapentin | 548 | 90 |
| Losartan Potassium | Losartan Potassium | 490 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 480 | 105 |
| Famotidine | Famotidine | 472 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 432 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 94 |
| Metformin Hcl | Metformin Hcl | 399 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 382 | 92 |
| Lisinopril | Lisinopril | 356 | 88 |
| Furosemide | Furosemide | 332 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 327 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 322 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 320 | 76 |
| Alprazolam | Alprazolam | 302 | 53 |
| Montelukast Sodium | Montelukast Sodium | 277 | 65 |
| Tramadol Hcl | Tramadol Hcl | 274 | 72 |
| Potassium Chloride | Potassium Chloride | 272 | 61 |
| Simvastatin | Simvastatin | 269 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 230 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 228 | 62 |
| Clonazepam | Clonazepam | 210 | 33 |
| Ezetimibe | Ezetimibe | 193 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 168 | 21 |
| Glimepiride | Glimepiride | 167 | 45 |
| Gemfibrozil | Gemfibrozil | 159 | 26 |
| Carvedilol | Carvedilol | 158 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 33 |
| Metformin Hcl Er | Metformin Hcl | 136 | 43 |
| Doxycycline Hyclate | Doxycycline Hyclate | 133 | 99 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 28 |
| Prednisone | Prednisone | 125 | 78 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 19 |
| Meloxicam | Meloxicam | 123 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 31 |
| Testosterone Cypionate | Testosterone Cypionate | 120 | 14 |
| Ozempic | Semaglutide | 118 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 112 | 26 |
| Spironolactone | Spironolactone | 112 | 19 |
| Jardiance | Empagliflozin | 108 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 107 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 105 | 29 |
| Eliquis | Apixaban | 99 | 26 |
| Warfarin Sodium | Warfarin Sodium | 96 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 95 | 19 |
| Sertraline Hcl | Sertraline Hcl | 94 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 44 |
| Celecoxib | Celecoxib | 88 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 86 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 23 |
| Trazodone Hcl | Trazodone Hcl | 85 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 37 |
| Azithromycin | Azithromycin | 83 | 70 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 83 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 24 |
| Ketoconazole | Ketoconazole | 76 | 33 |
| Memantine Hcl | Memantine Hcl | 76 | 18 |
| Methotrexate | Methotrexate Sodium | 76 | 14 |
| Meclizine Hcl | Meclizine Hcl | 75 | 39 |
| Fluconazole | Fluconazole | 71 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 15 |
| Farxiga | Dapagliflozin Propanediol | 68 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 14 |
| Promethazine Hcl | Promethazine Hcl | 67 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 56 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 13 |
| Azelastine Hcl | Azelastine Hcl | 64 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 14 |
| Atenolol | Atenolol | 63 | 19 |
| Divalproex Sodium | Divalproex Sodium | 63 | suppressed |
| Sucralfate | Sucralfate | 60 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 32 |
| Lactulose | Lactulose | 59 | suppressed |
| Lorazepam | Lorazepam | 57 | suppressed |
| Methocarbamol | Methocarbamol | 57 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 11 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Allopurinol | Allopurinol | 54 | 17 |
| Cefuroxime | Cefuroxime Axetil | 53 | 46 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 37 |
| Baclofen | Baclofen | 52 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | 17 |
| Synthroid | Levothyroxine Sodium | 52 | suppressed |
| Torsemide | Torsemide | 52 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 17 |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 14 |
| Amoxicillin | Amoxicillin | 48 | 39 |
| Doxepin Hcl | Doxepin Hcl | 48 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 47 | 15 |
| Alendronate Sodium | Alendronate Sodium | 46 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 13 |
| Mupirocin | Mupirocin | 44 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 13 |
| Olanzapine | Olanzapine | 42 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 12 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Finasteride | Finasteride | 33 | 12 |
| Levofloxacin | Levofloxacin | 32 | 30 |
| Olanzapine Odt | Olanzapine | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Nystatin | Nystatin | 31 | 21 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Ramipril | Ramipril | 26 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 14 |
| Digoxin | Digoxin | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 11 |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Dexamethasone | Dexamethasone | 21 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 16 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Pimozide | Pimozide | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $498.70 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error